In October 2020, Olema Pharmaceuticals announced a Series C Preferred stock financing of $85 million. The Company is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast and gynecologic cancers.
Deerfield Commits Up to $130 Million to Commercialize Drug Discovery at University of Michigan
(Ann Arbor, MI and New York, NY, May 27, 2020)—A new partnership between the University of Michigan (U-M) and health care investment firm Deerfield Management Co. will create a company to commercialize therapeutic projects that hold promise in solving unmet medical needs.
U-M and Deerfield on Wednesday announced the launch of Great Lakes Discoveries LLC. Deerfield has committed up to $130 million over the next decade to invest in biomedical research at U-M with the aim of developing potentially life-saving drugs and disease treatments.
“The University of Michigan has a strong legacy of drug discovery and translation,” said Rebecca Cunningham, U-M vice president for research. “This new alliance will allow us to advance these discovery and translational efforts, speeding our path to positive impact.”
As part of the alliance, Deerfield will deliver development expertise to help shepherd potential cutting-edge treatments in high-need therapeutic areas, as well as for rare diseases, with the objective of delivering more effective treatments to market. All preclinical stages of drug discovery and development of selected projects will be supported by Great Lakes Discoveries.
“We recognize that scientists at preeminent academic research institutions like the University of Michigan provide much of the novel insights that advance our understanding of disease,” said William Slattery, Deerfield partner. “However, at any research institution, the most commercially promising innovations eventually outgrow the lab, requiring greater resources and more focused development expertise than an academic setting can typically provide. We’re excited to have the University of Michigan join us in this important initiative.”
Starting this fall, U-M researchers will have the ability to submit proposals for review by a Great Lakes committee composed of scientific leadership representing both the university and Deerfield.
“We are excited to be able to collaborate with Deerfield in a way that will catalyze our translational research efforts by supporting preclinical and commercial clinical development of U-M therapeutics to improve patient care by developing transformative new therapeutics,” said Marschall Runge, dean of the U-M Medical School and executive vice president for medical affairs.
Projects selected by the committee will be provided funding and operational support by Deerfield for a development plan aimed at achieving Investigational New Drug (IND) readiness. Successful projects that achieve IND-enabled status may be eligible for additional capital from Deerfield. Great Lakes Discovery, in exchange for funding, would receive an option to license intellectual property that is developed at U-M under this agreement.
Kelly Sexton, U-M associate vice president for research-technology transfer and innovation partnerships, whose office will be overseeing the Deerfield alliance, said this new source of funding will be instrumental in helping advance drug candidates toward impact.
“The University of Michigan has one of the most massive academic therapeutic pipelines in the world, with 14 drug candidates currently in various stages of clinical trials and over 130 preclinical drug discovery, drug repurposing and novel drug target validation programs underway in our labs across campus,” Sexton said. “This funding will help us to realize the promise of this pipeline.”
Roger Cone, director of the Life Sciences Institute and the vice provost for the Biosciences Initiative at U-M, says the alliance complements U-M’s existing translational infrastructure.
“The University of Michigan has invested extensively in creating a world-class drug discovery machinery. This new alliance will complement and accelerate our efforts,” he said.
U-M alumnus James E. Flynn, managing partner at Deerfield and member of the U-M Life Sciences Institute’s Leadership Council, said “the current health crisis is a painful reminder to never become complacent in our fight against disease.”
“Part of this involves continuously identifying the most important early-stage research and ensuring its advancement in a timely way and without unnecessary barriers,” he said. “I’m confident that the University of Michigan shares this goal, as we join forces to catalyze the development of novel therapeutics and save lives. With its vast research platform, the University of Michigan is the ideal partner and we look forward to the innovations that we expect this alliance will bring.”
Deerfield Closes $840 Million Healthcare Venture Fund
The Deerfield Healthcare Innovations Fund ll will invest in advancements in science for promising therapeutics and to improve ways healthcare is delivered to patients
(New York, NY, April 6, 2020)—Deerfield Management Company, L.P. today announced the closing of the Deerfield Healthcare Innovations Fund ll, L.P., which will invest in advancements in science that may lead to important therapeutic interventions and back new technologies and infrastructure to improve the way healthcare is delivered to patients.
“Now more than ever, these unprecedented times underscore the importance of supporting the critical work of our nation’s scientists and healthcare systems,” said James E. Flynn, managing partner of Deerfield. “Our uniquely supportive model allows us to provide leverage to innovative companies and accelerate the benefit to patients.”
The Healthcare Innovations Fund II will collaborate with more than 15 leading academic institutions to seed novel scientific research. The Fund also has access to innovative medtech incubators created in partnership with two medical device industry leaders.
The Cure, the recently announced innovation campus located at 345 Park Avenue South, will become the central location of Deerfield where much of the work of the Healthcare Innovation Fund II will take place. Many of the early-stage companies will utilize the Cure’s wet and dry labs, engineering, computing and shared resource spaces.
The companies will also benefit from on-site programming, including the Fellows Program, Break into the Boardroom and Women in Science. Newly curated programs to be featured involve the “Cure Lounge,” a thought leadership and executive club, and other educational and certification initiatives.
The Deerfield Healthcare Innovations Fund ll is supported by the entire Deerfield infrastructure.
Deerfield has been investing in and supporting the healthcare industry for more than 25 years, and partner companies benefit from its organizational capabilities.
Today, Deerfield has more than 130 experienced healthcare-focused professionals with specialized knowledge in medicine, life sciences, drug and medical device development, healthcare markets, public policy, value-based care, financial instruments, tax, accounting, operations, corporate strategy, market access research, marketing, biostatistics and sector dynamics, all of which can be leveraged by its partners.
Together, Deerfield team members fully fund and manage the Deerfield Foundation, which to date has committed or invested over $49 million to global organizations seeking to improve the delivery of healthcare, with a focus on underserved children. The Deerfield Foundation recently committed approximately 10 percent of its 2020 fiscal budget toward COVID-19 emergency funding to organizations in need of urgent resources in order to provide care to their communities.
Deerfield is a healthcare investment management firm committed to advancing healthcare through investment, information and philanthropy.
Contact:
Media
Deerfield Management
Karen Heidelberger, 212-692-7140
[email protected]
-####-
Ablexis, LLC
In June 2018, Ablexis LLC, and Deerfield Management announced the acquisition of Ablexis by Deerfield. This acquisition creates a long-term partnership that will enable Ablexis to expand industry access to its AlivaMab® Mouse technology, the Company’s next-generation transgenic mouse platform for human antibody drug discovery.
